Mylan recalls 80,000 EpiPens manufactured by Pfizer, returning injector to the spotlight

Mylan's EpiPen
Mylan is recalling more than 80,000 EpiPens shipped outside of the U.S. after two confirmed reports pens did not work correctly.

Just as the furor over pricing had died down, the EpiPen is back in the spotlight with Mylan recalling more than 80,000 of the injectors outside the U.S. because they may not work.

The injectors were manufactured for Mylan by Pfizer’s Meridian Medical Technologies, a unit which has been at the center of unwanted attention for its injectors before.

Mylan this week issued a recall of four batches of its EpiPen 300 microgram injectors shipped to Europe, Japan, Australia and New Zealand. The recall followed two confirmed reports that the devices may contain a defective part that could result in the pen either not activating or requiring extra force to activate, the company said.


The 13th Annual Digital Pharma East

Digital Pharma East returns to the Pennsylvania Convention Center September 17–20, bringing together over 1000 attendees from biotech and pharma, to better understand how to present business plans, justify budget and innovation, and de-risk proposals getting shut down — essentially, understand how they can return to the office and become champions for their internal digital needs. Join us and save 15% on standard rates when you register with Discount Code DPE19Fierce.

That, as Mylan pointed out, could be a problem for someone being injected for anaphylaxis or anaphylactic reactions. It said that "at this time" its EpiPen Jr pens, its 150 pens and all of the EpiPen 300 injectors outside of the identified batches were okay to use. 

The pens were manufactured for Mylan by Pfizer’s Meridian unit in St. Louis, Missouri. The Pfizer operation ran into trouble with a Congressman in 2013 when it had to replace injectors sold to the military that were to be used in case of a sarin gas attack. Pfizer had discovered that about 7 out of 1,000 of its DuoDote auto-injectors containing atropine and pralidoxime didn't contain enough of one or both of the drugs.

At the time, there had been a confirmed report that Syria had used sarin in a rocket attack in its civil war that killed hundreds.  

The current recall comes as attention on EpiPen pricing has subsided somewhat. Mylan CEO Heather Bresch spent the second half of last year dealing with public and political outrage after reports showed Mylan had raised the price repeatedly for the pens as its lock on the market tightened. It also struck a $465 million settlement with the Justice Department to resolve allegations that it overcharged Medicaid for EpiPen.

Suggested Articles

The FDA lambasted Strides Pharma in a warning letter after inspectors found testing records in the trash and in bags by a shredder.

Chinese biotech CMBG hopes to get a cell manufacturing facility built in nine months and more manufacturing news of note.

Kite has been buying the viral vector starting material for its CAR-T treatment Yescarta from contractors but says it is time to produce its own.